Brokers Issue Forecasts for RAPT Q2 Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a report released on Thursday, May 22nd. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($0.08) per share for the quarter. HC Wainwright has a "Strong-Buy" rating and a $6.00 price objective on the stock. The consensus estimate for RAPT Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.

Other equities analysts also recently issued reports about the company. Wall Street Zen raised RAPT Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. UBS Group dropped their price objective on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, RAPT Therapeutics presently has a consensus rating of "Hold" and an average target price of $3.00.

RAPT Therapeutics Stock Down 20.7%

NASDAQ RAPT traded down $0.25 during mid-day trading on Monday, hitting $0.98. The stock had a trading volume of 3,456,655 shares, compared to its average volume of 1,285,946. RAPT Therapeutics has a 52-week low of $0.71 and a 52-week high of $4.60. The company has a market cap of $129.09 million, a price-to-earnings ratio of -0.35 and a beta of -0.04. The company has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.14.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.23.

Hedge Funds Weigh In On RAPT Therapeutics

Several hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC increased its stake in RAPT Therapeutics by 401.9% in the fourth quarter. SG Americas Securities LLC now owns 53,244 shares of the company's stock valued at $84,000 after purchasing an additional 42,636 shares during the last quarter. Sei Investments Co. acquired a new position in RAPT Therapeutics in the fourth quarter valued at $64,000. JPMorgan Chase & Co. lifted its stake in shares of RAPT Therapeutics by 1,128.3% during the fourth quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock worth $324,000 after purchasing an additional 188,461 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of RAPT Therapeutics by 25.5% during the fourth quarter. Renaissance Technologies LLC now owns 369,736 shares of the company's stock worth $584,000 after purchasing an additional 75,136 shares in the last quarter. Finally, Comerica Bank acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth about $92,000. Hedge funds and other institutional investors own 99.09% of the company's stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.